Dragon Pharma B7-33 10 mg is supplied as a lyophilized powder in a 2 mL vial and contains the synthetic peptide B7-33 at a labeled strength of 10 mg/vial. Product specifications, storage information, and other practical product details are provided below.
10 mg/Vial Strength
Each vial is labeled at 10 mg of B7-33 peptide.
2 mL Vial
Supplied as a lyophilized powder in a sealed 2 mL vial.
Lyophilized Form
Supplied as a freeze-dried powder for reconstitution with bacteriostatic water or suitable diluent.
Dragon Pharma
Manufactured and packaged under the Dragon Pharma product line.
Product Specifications
Product name
B7-33 10 mg
Active substance
B7-33
Labeled strength
10 mg/vial
Container
2 mL vial
Product form
Lyophilized powder
Manufacturer
Dragon Pharma
Related Products
Other research peptides available from Dragon Pharma include BPC-157 5 mg, a peptide investigated for tissue repair, and TB-500 5 mg, a peptide related to actin regulation. Each has a distinct research profile and mechanism of action.
Science & Research
Understanding B7-33
B7-33 is a synthetic, single-chain peptide derived from the B-chain of human relaxin-2 (H2 relaxin). It acts as a selective agonist for the relaxin family peptide receptor 1 (RXFP1), a receptor involved in various physiological processes including vasodilation, tissue remodeling, and fibrosis regulation.
1
RXFP1 Agonist
B7-33 selectively binds to and activates the relaxin family peptide receptor 1 (RXFP1).
2
Relaxin Signaling Mimicry
B7-33 mimics the receptor activation of native relaxin-2, stimulating downstream signaling pathways involved in vasodilation and tissue remodeling.
3
Research Applications
B7-33 is being studied for its potential anti-fibrotic, cardioprotective, and vasoprotective properties in preclinical models.
Mechanism of Action
B7-33 is a synthetic peptide designed to selectively activate the relaxin family peptide receptor 1 (RXFP1). By binding to this receptor, B7-33 mimics the signaling of native relaxin-2, which activates intracellular pathways involved in vasodilation, anti-fibrotic processes, and tissue remodeling.
The development of B7-33 as a selective RXFP1 agonist was driven by the need for a more stable and potentially more selective compound compared to native relaxin-2. The peptide's single-chain structure contributes to its research utility.
Research Context
In preclinical models, B7-33 has been investigated for its potential to modulate fibrotic processes, support cardiovascular function, and influence vascular health. These areas of investigation are part of ongoing research into relaxin receptor signaling and its therapeutic implications.
Dragon Pharma B7-33 10 mg is supplied as a lyophilized powder in a 2 mL vial at a labeled strength of 10 mg/vial.
Research References
B7-33 has been the subject of preclinical research investigating its pharmacology and potential applications. Published literature provides information on the compound's properties and mechanism of action.
B7-33 is a bioactive research peptide with limited safety data in humans. As a peptide involved in vasodilation and tissue remodeling pathways, its use requires appropriate consideration of potential physiological effects.
Cardiovascular Effects
As an RXFP1 agonist, B7-33 may influence vasodilation and blood pressure. Individuals with cardiovascular conditions should exercise caution.
Injection Site Reactions
Reconstituted peptides may cause localized reactions at the injection site. Proper aseptic technique is essential for preparation and administration.
Pregnancy and Breastfeeding
B7-33 is not indicated for use during pregnancy or breastfeeding. Its effects on fetal development and infant health are not established.
Unknown Risks
As a research compound, the long-term safety profile of B7-33 is not fully established. Unknown risks may exist.
Conditions That Require Medical Review
Medical advice is particularly important when there is a history of cardiovascular disease, blood pressure abnormalities, or when taking medications that may interact with vascular pathways.
The product should also be stored securely to prevent accidental access or use by children or other household members.
When to Seek Urgent Medical Help
Seek urgent medical attention for symptoms such as severe allergic reactions, chest pain, sudden shortness of breath, fainting, severe headache, or significant changes in blood pressure.
Tested Sport
B7-33 is not currently listed on the WADA Prohibited List. However, the use of peptides and research compounds may be subject to specific anti-doping rules depending on the sport and governing body. Current requirements should be checked against the relevant anti-doping rules before competition.
Quick answers about B7-33 10 mg specifications, storage, shipping, Bitcoin payment and general product information.
What is Dragon Pharma B7-33 10 mg?
Dragon Pharma B7-33 10 mg is a lyophilized peptide product containing B7-33 at a labeled strength of 10 mg per vial. It is supplied in a 2 mL vial as a freeze-dried powder.
What is B7-33?
B7-33 is a synthetic single-chain peptide derived from the B-chain of human relaxin-2. It acts as a selective agonist for the relaxin family peptide receptor 1 (RXFP1) and is investigated for its potential anti-fibrotic and cardioprotective properties.
How is B7-33 10 mg supplied?
It is supplied as a lyophilized powder in a 2 mL vial. The product must be reconstituted with a suitable diluent such as bacteriostatic water before use in a research setting.
What is the difference between B7-33 and native relaxin-2?
B7-33 is a synthetic single-chain peptide derived from the B-chain of relaxin-2. It is designed to selectively activate the same receptor (RXFP1) while having a distinct structure from the full native hormone.
Is B7-33 10 mg FDA approved?
No. B7-33 is not FDA-approved for any therapeutic use. It is a research compound intended for laboratory and preclinical research purposes only.
How should B7-33 10 mg be stored?
Keep the lyophilized powder in its original packaging and protect it from excessive heat, moisture and direct light. Refer to the product label for specific storage directions regarding temperature and shelf life. Once reconstituted, the solution should be used promptly or stored according to the manufacturer's directions.
Does B7-33 10 mg require refrigeration?
Follow the storage instructions printed on the supplied product. Lyophilized peptides often require refrigeration, but specific storage conditions should be verified from the product label.
How long does B7-33 10 mg delivery take?
Delivery depends on the warehouse selected for the order. Shipments from the USA Warehouse typically take 4–5 business days after dispatch, while shipments from the International Warehouse typically take 15–20 business days after dispatch. Full delivery and reship information is available on the Shipping Information page.
Can I buy B7-33 10 mg with Bitcoin?
Yes. Bitcoin and other supported cryptocurrencies are available at checkout for all orders. To buy B7-33 10 mg with Bitcoin, select Bitcoin as the payment method during checkout and follow the payment instructions provided with the order.
Is Bitcoin payment anonymous?
Bitcoin transactions are recorded on a public blockchain and should not be considered automatically anonymous. Accurate order and delivery information is still required for order processing and shipping.
Is B7-33 permitted in tested sport?
B7-33 is not currently listed on the WADA Prohibited List. However, the use of peptides and research compounds may be subject to specific anti-doping rules depending on the sport and governing body. Current requirements should be checked against the relevant anti-doping rules before competition.
Where can I find more information about B7-33?
Additional information about B7-33 is available through PubMed and other research literature databases. Direct links are provided in the Science & Research section above.
